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Abstract
Testis tumors occur frequently in dogs. The main types of tumors are Sertoli cell tumors,
seminomas, and Leydig cell tumors. Mixed tumors and bilateral occurrence of tumors may be
encountered frequently. To elucidate the possible relationship between the insulin-like growth
factor (IGF) system and the development of different types of testis tumors in dogs, the expression
of insulin-like growth factor-I and II (IGF-I and IGF-II), their type I receptor (IGF-IR), and their
binding proteins (IGFBPs) was examined. In addition the expression of the steroidogenic enzymes
p450-aromatase and 5α-reductase type I and type II, and the androgen receptor (AR) was
investigated by a semiquantitative reverse-transcriptase PCR (RT-PCR). Both normal testes and
testes with tumors were studied. In normal testes a clear expression of IGF-I, IGF-II, IGF-IR,
IGFBP2, IGFBP4 and IGFBP5 was found. Expression of IGFBP1 and IGFBP3 was weak. There was
also clear expression of the steroidogenic enzymes 5α-reductase, aromatase, and the AR.
Quantification of RT-PCR products revealed significantly less expression of IGFBP1, IGF-I, and 5α-
reductase type I in Sertoli cell tumors and seminomas. Leydig cell tumors and mixed tumors had a
significantly higher expression of IGFBP4 and IGF-IR than normal testes. The expression of
aromatase was lower in seminomas and in mixed tumors. The expression of AR, IGF-II and IGFBP2,
IGFBP3, IGFBP5, and 5α-reductase type II did not differ among the different types of tumors. It was
concluded that Sertoli cell tumors and seminomas have a comparable expression of the IGF system
while Leydig cell tumors have a different pattern, suggesting difference in pathobiology among these
types of tumors.
Background
The prevalence of testicular tumors is higher in dogs than
in any other species of domestic animals and higher than
in humans. Especially in older dogs the prevalence can be
as high as 60% [1]. Testis tumors in dogs seldom metasta-
size and can be considered to be benign proliferations [2].
The three main types of testis tumors in dogs are Sertoli
cell tumors, seminomas, and Leydig cell tumors and
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dom lethal, but can cause feminization of the dog, which
in severe cases can lead to a fatal bone marrow depression
[2]. Feminization is caused by hyperestrogenism and is
mostly associated with Sertoli cell tumors but Leydig cell
tumors and seminomas have also been associated with
this syndrome. When feminization occurs in dogs with a
seminoma, it is presumed that a co-existing Sertoli or Ley-
dig cell tumor is responsible for the hyperestrogenism [2].
There is evidence that growth factors of the insulin-like
growth factor regulatory system, such as insulin-like
growth factor-I (IGF-I) and IGF-II, are involved in the
pathobiology of neoplasia, both in terms of the risk of de-
veloping a tumor and in terms of its behavior [3].
Insulin-like growth factor-I (IGF-I) and IGF-II are peptides
believed to play an important role in the regulation of cel-
lular growth and differentiation. The IGFs are synthesized
and secreted by many tissues. They can act as endocrine
hormones that are being transported by the circulation to
distant sites of action, but they can also act locally by para-
crine or autocrine mechanisms. The biological activity of
IGF-I and IGF-II is modulated by their binding proteins
and receptors. Two distinct receptors and six different
high-affinity binding proteins have been identified [4,5].
Both IGF-I and IGF-II are produced locally in the testis [6–
9]. The IGF system plays an important role in the local reg-
ulation of testicular function [10]. IGF-1 has different
roles in the two major compartments of the testis, the in-
terstitium containing the Leydig cells and the seminifer-
ous tubules containing Sertoli and germ cells. In Leydig
cells it stimulates testosterone synthesis [11], in spermato-
gonia it is involved in stimulation of DNA synthesis [12],
while in Sertoli cells it stimulates lactate synthesis [13]
and glucose transport [14]. IGF-II has a clearly established
role in embryonic and fetal development, but its postnatal
function remains unclear [15] although culture experi-
ments have shown that it can stimulate spermatogonial
proliferation [12].
Two major gene classes, the proto-oncogenes and tumor
suppressor genes, can trigger tumor formation after be-
coming mutated. It is known that components of the IGF
system are upregulated by oncogenes, while tumor sup-
pressor genes can inhibit this system [16]. Hence, mutated
proto-oncogenes may induce the abundant synthesis of
growth factors like the IGF's [17]. Subsequently, autocrine
regulation of growth can occur in a number of tumors, im-
plying that the tumor cells have gained the ability to grow
autonomously [18]. Since mixed tumors are encountered
frequently in the canine testis, one could argue that both
autocrine and paracrine mechanisms may play a role in
tumor induction [19]. This could raise the hypothesis that
neighboring cells following several mutations could be
triggered to transform and become neoplastic even if they
are of different origin, leading to formation of different
types of tumors in one testis.
When investigating a model for carcinogenesis, testis tu-
mors could be considered as hormone-related cancers
whereby hormones drive cell proliferation. Genes in-
volved in steroid hormone metabolism and transport are
of interest. We investigated four genes: p450-aromatase,
the androgen receptor and 5α-reductase type I and II. The
p450-aromatase (P450-aro) enzyme converts testosterone
to estrogens, the androgen receptor is responsible for an-
drogen transport and 5α-reductase is responsible for the
conversion of testosterone to the metabolically more ac-
tive dihydroxytestosterone (DHT). Two isoforms of 5α-re-
ductase have been identified and are referred to as type I
and type II. The formation of DHT is IGF-I dependent
[20].
Because tumors occur more frequently in the canine testis
than in any other species we hypothesize that the IGF-sys-
tem is stimulated in the testis of the aging dog. To test this
hypothesis we examined the gene expression of IGF-I,
IGF-II, and IGF-IR and the binding proteins IGFBP1 to
IGFBP5 in Sertoli cell tumors, seminomas, Leydig cell tu-
mors, and mixed tumors. Furthermore, we also studied
the expression of the enzymes p450-aromatase and 5α-re-
ductase (type I and II) and the androgen receptor, which
may be indicative of differentiation induced by the IGF
system.
Materials and Methods
Material
Twenty-four dogs with testis tumors and 6 dogs with nor-
mal testes were studied. Approval of the ethical committee
of the University of Utrecht for the use of the animals for
research was obtained. The testes were collected from sev-
eral veterinary clinics and a hign number of different
breeds of dogs were included in this study. The age of the
dogs varied from 3 to 14 years. Bilateral orchidectomy was
performed except in 2 dogs in which only one testis was
present. Four dogs had signs of feminization. Tumors
were dissected free as well as possible, cut in pieces, and
immediately placed in liquid nitrogen. One piece of tu-
mor material was fixed by immersion in Bouin's solution
for at least 24 hours. If a (macroscopically) nonhomoge-
nous tumor was present, more pieces of tissue were fixed.
The frozen pieces were stored at -70°C until further
processing.
Characterization of tumors
The pieces of tissue fixed by immersion were embedded in
paraffin and sections were cut at 5 µm. Sections were
stained with Mayer's hematoxylin and eosin forPage 2 of 8
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stained with an antibody against the LH receptor which is
characteristic for Leydig cells in the testis [21]. An anti-
body against vimentin was used to identify Sertoli cells.
This antibody does not stain seminoma cells in dog testes
and can, therefore, be used to discriminate between Serto-
li cells and seminoma cells [22] as was described in an ear-
lier study [21].
Immunohistochemical staining was also performed with
frozen material. Frozen pieces of tumorous testis tissue
were cleaved, one half being used to prepare cryostat sec-
tions of 5 µm, which were stained with the antibody
against LH receptor, and the other half being used to study
gene expression.
Tissue processing for RNA isolation and RT-PCR
Frozen pieces of testicular and tumorous tissue were
weighted. About 1 g of frozen material was transferred to
a liquid-nitrogen-cooled container and ground thorough-
ly with a dismembrator (Braun Biotech Int., Melsungen,
Germany) for 45 s at 2200 rpm. Tissue powder was de-
canted into another liquid-nitrogen-cooled tube and
stored at -70C°. When necessary the remaining material
was homogenized again for 45 s with the dismembrator.
This step was repeated until all pieces were completely
ground into powder.
Total RNA isolation was performed using the Qiagen
RNeasy Maxi Kit (Westburg, Leusden, The Netherlands).
Reverse transcription of the poly (A)+ RNA was performed
with a reverse transcription system (Promega Corpora-
tion, Madison, WI). Five µg of total RNA was used for this
reaction in a mixture of 30 µl 25 mM MgCl2, 10 µl 10 ×
AMV-RT buffer, 10 µl 10 mM dNTPs, 100 units RNasin
RNase inhibitor, 75 units AMV reverse transcriptase, 2.5
µg oligo 15(dT) primer, and RNase free water to a final
volume of 100 µl. The reaction occurred for 60 min at
42°C followed by 5 min at 95°C. For the PCR reaction 10
µl of the RT-PCR mixture together with 1.25 units Taq
DNA polymerase (Promega), 4 µl 10 × PCR buffer
(Promega), and 10 pmol of each primer were combined.
Sterile water was added to a final volume of 50 µl. Primers
for aromatase, 5α-reductase, androgen receptor, IGF-I,
IGF-II, IGF-IR, and IGFBP1 to IGFBP5 were used for the
different reactions (Table 1).
A PCR with sterile water with or without RT mixture was
used as a negative control. The numbers of cycles were
chosen in such a way that the reactions were in the expo-
nential phase of the amplification reactions, enabling a
semiquantitative evaluation of the results. For this pur-
pose several tests were carried out with 20, 25, 30, and 35
cycles to estimate the linear section. PCR was performed
in a Perkin Elmer Cetus or a MJ Biozym thermal cycler
using 30 or 35 cycles of denaturation (94°C, 1 min; first
cycle 94°C, 5 min), annealing (55–60°C, 1 min) and
extension (72°C, 1 min) followed by a final extension of
10 min at 72°C (Table 2).
Fifteen µl of all PCR products were separated on 1.2% aga-
rose gels stained with ethidium bromide and photo-
graphed under UV illumination using a CCD camera. The
DNA molecular weight marker VI was used as a size mark-
er (Boehringer, Mannheim, Germany). Photographs were
scanned and band intensities were measured using Molec-
ular Analyst software (BioRad Laboratories, Veenendaal,
The Netherlands). Fragment sizes were quantified and
compared with that of negative controls. Per pair of prim-
ers all samples were separated on one gel and each gel
contained a negative control.
Table 1: Primer sequences
Primer Size Sense Antisense
Aro 419 CCCACTTCAGGTTCCTCTGGATGG TGTTAGAGGTGTCCAGCATG
AR 598 CCGTGAGCGCAGCACCTCCCGGTG TGCTCTCCCGCTGCTGCTACCTTCTG
IGF-I 350 ATGTCCTCCTCGCATCTCTT TCCCTCTACTTGCGTTCTTC
IGF-II 450 TTGGCCTTCGCCTCGTGCTG GGACGGTGACGCTTGGCCTCTCTG
IGF-IR 437 AAATGTGCCCGAGCGTGTG TGCCCTTGAAGATGGTGCATC
Red 1 213 CTGAGGAATCTCCGAAAACC TCTAAGGTACCACCGGTGAT
Red 2 250 TCACTAGAGGGAGGCCTTTTC ACAAGCCACCTTGTGGAATC
IGFBP1 240 ATAACTCAGGAGCAGCTTCTGG TCTTGTTGCAGTTTGGCAG
IGFBP2 553 AACGGCGAGGAGCACTCTGA AGGCACCGGCTGGCTATGTT
IGFBP3 200 AGTGAGTCCGAGGAGGACC GACTCAGAGGAGAAGTTCTGGG
IGFBP4 513 CTGCGGTTGTTGTGCCACTTGC CAGCATTTGCCACGCTGTCCATC
IGFBP5 484 GCAGGACGAGGAGAAGCCGC TCCACGCACCAGCAGATGCC
Aro = p450-aromatase enzyme, AR = androgen receptor, IGF = insulin-like growth factor, IR = receptor type I, Red 1 = type I 5α-reductase 
enzyme, Red 2 = type II 5 α reductase enzyme, IGFBP = binding protein.Page 3 of 8
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nator Cycle Sequencing kit (Applied Biosystems, Foster
City, CA, USA). For sequence analysis an ABI Prism 310
genetic analyzer (Applied Biosystems, Foster City, CA,
USA) was used. Sequences were matched with the Gen-
Bank using the Blast Search program in order to be certain
that the correct products were identified.
Statistical Analysis
Dogs with different types of tumors were compared sepa-
rately with dogs with normal testes. Dogs with mixed tu-
mors were not evaluated according to the type of tumor
but as one group. Differences were evaluated statistically
using SSPS 7.5 software. A one-way Anova was used with
post hoc tests (LSD) to analyze differences between tumors
and normal testes. Differences were considered to be sig-
nificant when p < 0.05.
Results
Characterization of testis tumors
Immunohistochemical characterization of the tumors
with Leydig cell specific antibodies against the LH-recep-
tor and 3β-hydroxy steroid dehydrogenase (3β-HSD) and
the Sertoli cell specific vimentin antibody revealed that 7
dogs had Leydig cell tumors, 7 had seminomas, 6 had Ser-
toli cell tumors and 4 had mixed tumors. The mixed tu-
mors consisted of 2 combinations of Sertoli cell tumor
and Leydig cell tumor and 2 combinations of seminoma
and Leydig cell tumor. There were bilateral tumors in 9
dogs. Seven of these dogs had identical tumors in both
testes. These were Sertoli cell tumors (4 dogs), seminomas
(1 dog), Leydig cell tumors (1 dog), and mixed Sertoli cell
tumor and Leydig cell tumor (1 dog). Two dogs had a Ser-
toli cell tumor in the left testis and either a Leydig cell tu-
mor or a seminoma in the right testis.
In 3 dogs with a Sertoli cell tumor and 1 dog with a Leydig
cell tumor there were signs of feminization.
Expression of genes
In the normal testes as well as in testis tumors, a clear ex-
pression was found by RT-PCR analysis of IGF-I, IGF-II,
IGF-R and the binding proteins IGFBP2, IGFBP4, and
IGFBP5. The expression of IGFBP1 and IGFBP3 was rela-
tively low or absent (Fig. 1). There was also a clear expres-
sion of both types of the 5α-reductase enzyme (types I and
II), the androgen receptor, and p450-aromatase (Fig. 1).
Compared to normal testes Sertoli cell tumors and semi-
nomas had significantly lower expression of IGFBP1, IGF-
I, and 5α-reductase type 1. Seminomas also had a signifi-
cantly lower expression of aromatase (Table 3). No differ-
ences were found with regard to the other genes
investigated. Thus, except for aromatase the expression
patterns of these two different types of tumors were very
similar. Compared to normal testes Leydig cell tumors
and mixed tumors had a significantly higher expression of
IGFBP4 and IGF-IR (Table 3). The expression pattern of
the mixed tumors was quite similar to that of the Leydig
cell tumors. The expression of aromatase was significantly
lower in dogs with mixed tumors than in dogs with nor-
mal testes (Table 3).
In three Sertoli cell tumors and one Leydig cell tumor of
dogs that showed feminization there was no increase in
the aromatase expression.
Discussion
RT-PCR analysis revealed a clear expression of the andro-
gen receptor (AR), aromatase, IGF-I, IGF-II, 5α-reductase
type I and II, and IGFBP5 in almost all samples from dogs
with testis tumors and from dogs with normal testes.
There was a less pronounced but still visible expression in
Table 2: PCR schedule
Primer Temperature Cycles Magnesium Gel %
Aro MJ 55°C 35 1.5 mM 1.2
AR PE 55°C 30 1.5 mM 1.2
IGF-I PE55°C 35 1.5 mM 1.2
IGF-II PE55°C 35 1.5 mM 1.2
IGF-IR PE58→50°C 35 1.5 mM 1.2
Red 1 55°C 35 3.0 mM 1.0
Red 2 55°C 35 3.0 mM 1.5
IGFBP1 58→50°C 35 1.5 mM 1.5
IGFBP2 60→55°C 35 1.5 mM 1.2
IGFBP3 55°C 35 4.0 mM 1.5
IGFBP4 55°C 30 1.5 mM 1.2
IGFBP5 55°C 30 1.5 mM 1.2
Aro = p450-aromatase enzyme, AR = androgen receptor, IGF = insulin-like growth factor, IR = receptor type I, Red 1 = type I 5α-reductase 
enzyme, Red 2 = type II 5 α reductase enzyme, IGFBP = binding protein, MJ = MJ biozym thermal cycler, PE = Perkin Elmer Cetus.Page 4 of 8
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only a few samples there was a clear expression of IGFBP1
and IGFBP3. Care was taken to limit the number of cycles
for the RT-PCR in order to remain within the linear part of
the amplification reaction. It should be stressed that the
results have to be interpreted as semiquantitative and with
caution. Nevertheless, using the RT-PCR technology, indi-
cations of changes in gene expression patterns can be
evaluated.
Earlier studies have shown expression of most genes of the
IGF system in mammary gland tissue of dogs [23,24]. To
the best of our knowledge, this is the first report of the ex-
pression of genes of the IGF system in the canine testis,
implicating that this system may play a role in the adult
canine testis. In the human and rat testis it has been
shown that the IGF system is expressed and plays an im-
portant role in testicular functioning [9,25].
In the present study differences in the expression of sever-
al genes of the IGF system were observed between normal
testis tissue and the different types of testicular tumors.
IGF-I and IGFBP1 expression were reduced in Sertoli cell
tumors and seminomas. IGFBP4 and IGF-RI mRNA levels
were not different from normal dog testes. In contrast to
these observations, IGF-I and IGFBP1 mRNA levels were
increased in human neoplastic tissues, where the IGF sys-
tem is believed to play a role in tumorgenesis [26–28]. Al-
though it does not seem likely that the IGF system plays
an important role in the development of canine Sertoli
cell tumors and seminomas, measurement of IGF, IGF-RI
and IGFBP proteins in tumor tissue should be carried out
to elucidate a possible role of this system in development
of these two types of tumors.
In dogs with a Leydig cell tumor, or mixed tumors with a
Leydig cell component, significantly higher IGF-IR and
IGFBP4 expression was observed. IGFBP's may compete
with the IGF-R's for binding of the available IGF. In cul-
tured porcine Sertoli cells an increase in IGFBP3 has been
shown to result in a decrease in bioactive IGF, suggesting
that IGF binds with higher affinity to the binding protein
than to its receptor [29]. Hence, although IGF-I mRNA
levels were not different from normal testes tissue in dogs
with Leydig cell tumors and mixed tumors, we can not ex-
clude that the modulation of IGF-I action may be different
among these groups of dogs, due to changes in IGFBP4
and IGF-IR mRNA levels. Moreover, we have only meas-
ured the IGF-I, IGF-RI and IGFPB mRNA levels in testes of
dog with large tumors. We can not exclude the possibility
that the initial growth phase of the tumors coincides with
elevated levels of some of the members of the IGF system,
followed by a decrease when the tumor ceases to grow or
when tumor growth is reduced. This needs to be further
investigated.
In general the changes observed in the expression of the
IGF system among the different types of tumors is not very
dramatic when compared to normal testis tissue. This
does not make it likely that this system plays an important
role in tumor maintenance and growth. In order to deter-
mine whether the IGF system is involved in the initiation
of tumor development in the canine testis, mRNA levels
should be determined from middle aged dogs to old dogs
when the chance of tumor development increases dramat-
ically. IGFs are also known to contribute to the process of
tumor metastasis by stimulating the motility of malignant
cells [30]. Since testicular tumors in dogs are usually not
malignant [2], it could be argued that the relatively nor-
mal expression levels of the IGF system contributes to the
low tendency to metastasize in this species.
The lower expression of 5α-reductase type I in dogs with
Sertoli cell tumors and seminomas compared to dogs with
Figure 1
RT-PCR products of canine testis tumors. IGF = insulin-like 
growth factor; IGF-1R = insulin-like growth factor receptor 
type 1; IGF-BP = insulin-like growth factor binding protein; 
ARO = p450-aromatase enzyme; RED = 5α-reductase 
enzyme type I (RED-1) and type II (REDII); AR = androgen 
receptor; Lanes 1–12: random samples of canine testicular 
tumours.Page 5 of 8
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gens. The 5α-reductase enzymes type I and type II which
convert testosterone to the metabolically more active
form dihydroxytestosterone (DHT), are localized in testic-
ular tissues [31,32]. Since the conversion of testosterone
in DHT is IGF-1 dependent [20]. The reduction of 5α-re-
ductase expression in Sertoli cell tumors could be a result
of the lower IGF-1 expression. In human skin fibroblasts
an increase in IGF-I levels has been shown to cause a rise
in 5α-reductase activity [33]. It is not likely that the semi-
noma cells themselves express 5α-reductase, hence, the
decreased 5α-reductase expression in these tumors is pre-
sumably the result of the reduced number of Sertoli cells
and Leydig cells present in the tumor.
Seminomas and mixed tumors had a lower expression of
aromatase than normal testes tissue, while the expression
in Sertoli cell tumors and Leydig cell tumors was compa-
rable to that in normal testes even when signs of femini-
zation were present. A comparable expression of
aromatase in these tumors was a rather unexpected find-
ing, since the presence of both Sertoli cell tumors and
Leydig cell tumors in dogs can result in elevated estradiol
levels, sometimes even causing feminization [34]. In oth-
er mammals, including man, aromatase has been found
in Leydig and Sertoli cells as well as in germ cells [35],
while in the equine testis only Leydig cells have been
shown to contain aromatase activity [36]. There are sever-
al possible explanations why aromatase expression in
dogs with Sertoli cell tumors and Leydig cell tumors is
comparable to that in normal dogs, although the level of
estradiol in peripheral and testicular venous blood was
elevated [37]. First, the aromatase enzyme is not the rate-
limiting step in the formation of estrogens unless it
becomes saturated. A condition that is very unlikely to
happen since the level of testosterone in dogs with Sertoli
cell tumors is very low [37]. Second, due to the reduced
5α-reductase type I expression, there is more testosterone
substrate available for the aromatase enzyme to convert to
estradiol, since both enzymes use androgens as substrate.
Third, there may be no correlation between aromatase ac-
tivity and thus estrogen synthesis, and aromatase mRNA
expression in canine testicular tumors, as was demonstrat-
ed in the epididymis of monkeys[38]. Fourth, the level of
the catabolic 17beta-HSD enzyme, that is able to convert
estradiol to estrone, can become down-regulated in path-
ological testis tissue leading to an accumulation of estra-
diol. This issue obviously needs more research in order to
clarify the discrepancy between aromatase mRNA expres-
sion and estradiol levels in serum.
We did not observe differences in the expression of the an-
drogen receptor among the different types of tumors. The
androgen receptor has been implicated to play a role in
neoplastic transformation of the prostate in men [39] and
by its presence in neoplastic germ cells, a role in the
pathogenesis of male germ cell tumors has also been sug-
gested [40]. Expression of the androgen receptor in the ca-
nine testis has been examined in a previous study. These
authors were unable to detect androgen receptors in be-
nign Leydig cell tumors, while malignant Sertoli cell tu-
mors and seminomas were characterized by higher
androgen receptor levels [41]. We investigated only be-
nign tumors, which may explain the differences between
our findings and the study mentioned above.
In conclusion, the expression of genes of the IGF system
has some different features in canine testis tumors com-
pared to normal testis tissue. Similar expression patterns
for IGF-I and IGFBP1 were found for Sertoli cell tumors
and seminomas, suggesting the possibility of a common
pathobiology. Leydig cell tumors and mixed tumors, all of
which contained Leydig cell tumor components had a dif-
ferent expression pattern, in these tumors the expression
of IGF-RI and IGF-BP4 was increased. However, the ob-
served changes in gene expression were all relatively
Table 3: RT-PCR analysis of canine testis tumors. PCR products were separated on agarose gels containing ethidium bromide. The gels 
were photographed and scanned and then relative band intensities were measured with software from Molecular Analyzer and 
expressed as volume counts per mm2 ± the standard error of means.
Diagnosis ARO IGFBP1 IGFBP4 IGF-1 IGF1-R RED 1
SCT (n = 15) 20.4 ± 8.8 10.7 ± 5.4* 17.9 ± 12.2 26.3 ± 12.1* 5.6 ± 2.2 41.3 ± 23.3*
SEM (n = 7) 17.0 ± 2.9* 8.7 ± 6.5* 17.0 ± 15.1 27.1 ± 8.0* 10.4 ± 4.1 38.3 ± 17.9*
LCT (n = 9) 19.4 ± 10.6 16.0 ± 4.9 33.3 ± 18.5* 35.4 ± 11.5 21.3 ± 3.2* 66.7 ± 20.6
MIXED (n = 5) 13.4 ± 5.3* 20.8 ± 9.4 36.8 ± 17.3* 30.8 ± 10.4 22.3 ± 8.4* 66.6 ± 6.7
NORMAL (n= 13) 27.6 ± 2.8 17.4 ± 9.4 19.5 ± 11.3 37.3 ± 9.3 7.9 ± 1.2 69.0 ± 15.9
SCT = Sertoli cell tumor, SEM = seminoma, LCT = Leydig cell tumor, mixed = a combination of testis tumors, ARO = p450-aromatase enzyme, 
IGFBP = insulin-like growth factor binding protein, IGF = insulin-like growth factor, IGF1-R = insulin-like growth factor receptor and RED 1 = 5α 
reductase type I. The number of tumors included in the measurements is indicated between brackets. Asterisk indicates significant difference 
between the tumor and the normal testis (p < 0.05).Page 6 of 8
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is important for tumor maintenance and growth in the
dog testis. Whether this system is involved in the initia-
tion of tumor growth is subject to further investigation.
Furthermore, signs of feminization cannot be attributed
to increased expression of aromatase mRNA levels. In or-
der to obtain more insight in this complicated model of
multiple tumor induction in the canine testis, additional
research in necessary.
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